Leucid Bio
leucid.com
Actively hiring
Biotechnology
Oncology Therapeutics
Health Care
As featured in
Follow
Overview
News
Salaries
Products
People
Growth
Offices
Financials
Funding and backers
Backers
1
Epidarex Capital
Momentum
0/100
no fresh signals
Last sign of life
this month
a posting or a news item
Backed byfrom the funds' portfolios and accelerator catalogs
Epidarex Capital Similar startupsby what they do, their industry and backers
Innovating life-changing medicines for cancer patients. At Kumquat, we're on a mission to transform cancer treatment by delivering durable…
Alpheus is advancing a new therapeutic approach designed to improve outcomes while reducing treatment burden for patients and families.
Targeting the Tumor Ecosystem to address cancer drug resistance and improve patients’ lives.
Creating neoantigens by design… …to transform cancer treatments into cures. ATP IS DEVELOPING THE NEXT GENERATION OF TRANSFORMATIVE LIFE…
Yemaachi is creating the world's most diverse cancer bio-database to develop the next generation of cancer drugs that are effective in…
At ITM, precision drives everything - from isotope manufacturing to cancer treatment—improving outcomes and delivering what patients and…
Overview
CAR T therapies with more durable responses, improving treatment outcomes and saving the lives of patients with refractory cancers.
News
Leucid Bio to Use Lonza's Cocoon Platform for Automated Manufacturing of CAR T Cells Pharmaceutical Technology
Leucid Bio will collaborate with Lonza to use Lonza's Cocoon Platform for clinical and commercial manufacturing of CAR T cells for Leucid's lead candidate.
Read more
Report
Leucid Bio and Syenex Announce Strategic Collaboration for In Vivo CAR-T Cell Engineering
/PRNewswire/ -- Leucid Bio ("Leucid" or the "Company"), a privately-held biotechnology company developing innovative Chimeric Antigen Receptor T-cell (CAR-T)...
Read more
Report
Leucid Bio provides update on phase I/IIa AERIAL trial evaluating lateral CAR-T LEU011 to treat solid tumours
Leucid Bio provides update on phase I/IIa AERIAL trial evaluating lateral CAR-T LEU011 to treat solid tumours
Read more
Report
Leucid Bio Provides Update on Phase I/IIa AERIAL Trial Evaluating Lateral CAR-T LEU011 for the Treatment of Solid Tumours
Leucid Bio ("Leucid" or the "Company"), a privately-held biotechnology company developing innovative Chimeric Antigen Receptor T-cell (CAR-T) therapies using its proprietary lateral CAR platform, today provided an update on the Phase I/IIa AERIAL trial ev
Read more
Report
Leucid Bio Provides Update on Phase I/IIa AERIAL Trial Evaluating Lateral CAR-T LEU011 for the Treatment of Solid Tumours
Proof-of-concept established for LEU011 in the treatment of relapsed/refractory solid tumours LEU011 has been well tolerated, with disease control observed
Read more
Report
Pro access
Upgrade to see all 9 mentions
Upgrade to a paid plan to read every media mention of this company - funding news, awards, product launches and press releases from all the outlets writing about it.
Every media mention and press release
Funding news, awards and product launches
Fresh coverage from every outlet writing about the company
Upgrade now
Cancel anytime. Secure checkout. Instant activation.
Offices
Where the company hires and what each office is for
Cities
1
Hiring now
0
Countries
1
London
United Kingdom
Regional office
Great Maze Pond, London, ENG, SE1 9RT, GB